Selecta Biosciences Announces New Preclinical Gene Therapy Data at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 15, 2017 08:00 ET
|
Selecta Biosciences
Proof of Concept for Rare Disease Methymalonic Acidemia (MMA) Gene TherapyGene Therapy Dose Titration Enabled via SVP-Rapamycin Combination Treatment WATERTOWN, Mass., May 15, 2017 (GLOBE NEWSWIRE)...
Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the Society for Investigative Dermatology Conference
May 02, 2017 08:05 ET
|
Abeona Therapeutics Inc
--EB-101 Demonstrates Significant Wound Healing (defined as greater than 50% healed) in 100% of Treated Wounds (36/36) at 3 Months; 89% (32/36) at 6 months, 83% (20/24) at 12 months, 88% (21/24) at 24...
Selecta Biosciences Announces Presentations at the 20th Annual Meeting of the American Society of Gene & Cell Therapy
May 01, 2017 08:00 ET
|
Selecta Biosciences
WATERTOWN, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on developing biologic therapies that avoid unwanted...
Fate Therapeutics to Present at the 5th Annual Cell & Gene Therapy Investor Day
April 20, 2017 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, April 20, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Lonza and Selecta Biosciences Announce Manufacturing Agreement for Anc80-AAV-Based Gene Therapy for Treatment of Methylmalonic Acidemia
February 16, 2017 07:00 ET
|
Selecta Biosciences
BASEL, Switzerland and WATERTOWN, Mass., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Lonza Houston, Inc., a global leader in viral gene and cell therapy manufacturing, and Selecta Biosciences, Inc....
Voyager Therapeutics Announces Updates from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease
January 20, 2017 07:31 ET
|
Voyager Therapeutics
Cohort 3 Enrollment Complete with Increased Coverage of the Putamen Observed Cohort 3 On Track for Six-Month Data Update Mid-2017 CAMBRIDGE, Mass., Jan. 20, 2017 (GLOBE NEWSWIRE) -- Voyager...
Voyager Therapeutics Announces Positive Interim Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease
December 07, 2016 16:05 ET
|
Voyager Therapeutics
VY-AADC01 dose-dependently improved measures of motor function and enhanced response to levodopa at six and twelve months; administration of VY-AADC01 was well-tolerated Program on track to report...
Selecta Biosciences Presented Preclinical Data Applying SVP-Rapamycin in Gene Therapy at Annual Congress of the European Society of Gene and Cell Therapy
October 20, 2016 08:00 ET
|
Selecta Biosciences Inc
Data underscore potential of SVP-Rapamycin to enhance therapeutic benefit of gene therapies by mitigating unwanted humoral (antibody) and cellular immune responses WATERTOWN, Mass., Oct. 20, 2016 ...
UK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia A
October 13, 2016 16:01 ET
|
BioMarin Pharmaceutical Inc.
Phase 1/2 Study Expected to Resume by End of 2016 Requirement for Prophylactic Corticosteroids Removed SAN RAFAEL, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc....
Voyager Therapeutics Licenses Novel Gene Therapy Capsids from the California Institute of Technology
September 15, 2016 07:05 ET
|
Voyager Therapeutics
CAMBRIDGE, Mass., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the...